Pulse Biosciences, Inc. (PLSE)
Market Cap | 59.31M |
Revenue (ttm) | 1.86M |
Net Income (ttm) | -62.29M |
Shares Out | 29.80M |
EPS (ttm) | -2.16 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 175,790 |
Open | 2.23 |
Previous Close | 2.14 |
Day's Range | 1.95 - 2.25 |
52-Week Range | 1.41 - 29.16 |
Beta | 1.89 |
Analysts | Buy |
Price Target | 11.39 (+472.4%) |
Earnings Date | May 11, 2022 |
About PLSE
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 201... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for PLSE stock is "Buy." The 12-month stock price forecast is 11.39, which is an increase of 472.36% from the latest price.
News

Pulse Biosciences, Inc. Announces Changes to its Rights Offering
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System Powered by Nano-P...

Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 5.88% and 36.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pulse Biosciences Reports First Quarter 2022 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, to...

Pulse Biosciences, Inc. Announces Commencement of Rights Offering
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company, today announced that it has commenced its previousl...

Pulse Biosciences Schedules First Quarter 2022 Financial Results Conference Call for May 11, 2022
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, an...

Pulse Biosciences to Present New Data on Nano-Pulse Stimulation Procedure for Sebaceous Hyperplasia and for Focal Epi...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, to...

PLSE DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Pulse Biosciences, Inc. Investors to Secure Counsel ...
New York, New York--(Newsfile Corp. - April 18, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between Jan...

Deadline Today: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 to Contac...
Los Angeles, California--(Newsfile Corp. - April 18, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, In...

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Bios...
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming April 18, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors ...

Deadline Monday Notice: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 t...
Los Angeles, California--(Newsfile Corp. - April 15, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, In...

PLSE Final Deadline: ROSEN, A Leading Law Firm, Encourages Pulse Biosciences, Inc. Investors with Losses Exceeding $1...
New York, New York--(Newsfile Corp. - April 15, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between Jan...

PLSE DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Pulse Biosciences, Inc. Investors to Secure Counsel ...
NEW YORK , April 14, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 ...

Pulse Biosciences, Inc. Announces Rights Offering
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company, today announced that the Company's Board of Directo...

Deadline Monday Reminder: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000...
Los Angeles, California--(Newsfile Corp. - April 14, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, In...

Monday Deadline Notice: The Schall Law Firm Encourages Investors in Pulse Biosciences, Inc. with Losses of $100,000 t...
Los Angeles, California--(Newsfile Corp. - April 13, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, In...

PLSE MONDAY DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pulse Biosciences, Inc. Investors With Losses Ov...
New York, New York--(Newsfile Corp. - April 12, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between Jan...

PLSE Investors Have Opportunity to Lead Pulse Biosciences, Inc. Securities Fraud Lawsuit
LOS ANGELES, April 12, 2022 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against P...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pulse Biosciences, Inc. - PLSE
NEW YORK , April 11, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE). Such investors are advised t...

PLSE APPROACHING DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Pulse Biosciences, Inc. Investors With Losses to Sec...
New York, New York--(Newsfile Corp. - April 8, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between Janu...

ROSEN, Leading Investor Counsel, Encourages Pulse Biosciences, Inc. Investors to Secure Counsel Before Important Apri...
New York, New York--(Newsfile Corp. - April 5, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between Janu...

ROSEN, A LEADING LAW FIRM, Encourages Pulse Biosciences, Inc. Investors to Secure Counsel Before Important April 18 D...
New York, New York--(Newsfile Corp. - April 3, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between Janu...

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Pulse Biosciences, Inc. Investors With Losses to Secure Counsel Before Imp...
NEW YORK--(BUSINESS WIRE)-- #Biosciences--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 ...

ROSEN, A TOP RANKED FIRM, Encourages Pulse Biosciences, Inc. Investors to Secure Counsel Before Important April 18 De...
New York, New York--(Newsfile Corp. - April 1, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between Janu...

Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Lags Revenue Estimates
Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 22% and 6.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Pulse Biosciences Reports Fourth Quarter & Full Year 2021 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, to...